Biomarker: p16INK4aa

Histology type: endometrial carcinoma

Stage: aggressive endometrial carcinomas

Country: Norway

Region: Bergen

Followed up time :

Subgroup 1 name : absent/minimal nuclear p16 expression

Subgroup 1 number: 39

Subgroup 2 name: moderate/high nuclear p16 expression

Subgroup 2 number: 247

Conclusion: In conclusion, loss of nuclear p16 protein expression was associated with aggressive endometrial carcinomas and high proliferative activity (Ki-67) and was found to represent a strong and independent prognostic indicator. Methylation of the promoter region seems to be an uncommon mechanism of p16 inactivation in endometrial carcinoma.

Sample type : tissue

Sample method: Methylation analys，RT-PCR，immunohistochemistry

Expression pattern : Loss of nuclear expression

Funtion Uniprot: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

UniProt ID: Q8N726

UniProt Link: https://www.uniprot.org/uniprotkb/Q8N726/entry#function

Biological function from UniProt: Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway

Molecular function from UniProt:

Subcellular UniProt: #Mitochondrion #Nucleus

Alternative name from UniProt:

Caution: The proteins described here are encoded by the gene CDKN2A, but are completely unrelated in terms of sequence and function to cyclin-dependent kinase inhibitor 2A (AC P42771) which is encoded by the same gene.

Recommended name: Tumor suppressor ARF

Gene name from HGNC: CDKN2A (ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf)

HPA class: Cancer-related genes Disease related genes Human disease related genes Plasma proteins

AlphaFold DB: Q8N726

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q8N726

HPA link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A

Tissue specificity RNA from HPA: Tissue enhanced (choroid plexus, pituitary gland)

Tissue expression from HPA: Mainly nuclear expression in most tissues.

Single cell type specificity Cell type enhanced (Late spermatids, Pancreatic endocrine cells, Early spermatids, Respiratory ciliated cells, Basal respiratory cells, Club cells)

Immune cell specificity: Immune cell enhanced (T-reg)

Subcellular summary HPA Located in Nucleoli (Single cell variability)

Cancer prognostic summary HPA Prognostic marker in endometrial cancer (unfavorable), renal cancer (unfavorable), liver cancer (unfavorable) and head and neck cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology/endometrial+cancer

OMIM: 600160

OMIM link2: https://www.omim.org/entry/600160

HGNC ID: HGNC:1787

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787